Dublin, Dec. 21, 2016 -- Research and Markets has announced the addition of the "Glaucoma Drugs Price Analysis and Strategies - 2016" report to their offering.
Glaucoma Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Glaucoma market.
The research answers the following questions:
- What are the key drugs marketed for Glaucoma and their clinical attributes? How are they positioned in the Global Glaucoma market?
- What are the unit prices and annual treatment cost for Glaucoma therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Glaucoma drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Glaucoma?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Glaucoma including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Glaucoma
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Glaucoma market
- Glaucoma Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Glaucoma New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/kj6p6h/glaucoma_drugs
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical


Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Bank of America's $72.5M Epstein Settlement: What You Need to Know
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



